1. Revance Therapeutics is facing a class action lawsuit for misleading statements. 2. Shareholders bought RVNC stock from February 29 to December 6, 2024. 3. False disclosures regarding Teoxane partnership risk litigation and reputation. 4. The deadline to register as a lead plaintiff is March 4, 2025. 5. Investors may claim losses due to reported breaches in agreements.
The lawsuit indicates significant mismanagement, potentially affecting RVNC’s stock negatively. Past examples show major lawsuits often depress stock prices.
The class action could substantially impact investor trust and RVNC's market positioning. Legal disputes often cloud future prospects and affect stock valuations.
The immediate threat of litigation could lead to quick stock price declines. Similar scenarios in the past led to rapid price drops following lawsuits.
NEW YORK, Jan. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).
Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE: https://securitiesclasslaw.com/securities/revance-therapeutics-inc-loss-submission-form-2/?id=123375&from=4
CLASS PERIOD: February 29, 2024 to December 6, 2024
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance "the exclusive right to import, market, promote, sell and distribute Teoxane's line of dermal fillers; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; (iii) all the foregoing increased the risk that the tender offer would be delayed and/or amended; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
DEADLINE: March 4, 2025. Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/revance-therapeutics-inc-loss-submission-form-2/?id=123375&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of RVNC during the timeframe listed above, you will be enrolled in portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 4, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: The Gross Law Firm, 15 West 38th Street, 12th floor, New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903
SOURCE The Gross Law Firm